Kazuyuki Matsuda

Kazuyuki Matsuda

Auto-generated profile, based on publicly available information

Kazuyuki Matsuda

Department of Laboratory Medicine, Shinshu University Hospital, Matsumoto, Japan

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

18 October 2018 in Blood Advances
Verified
Journal Article
Closed access
PDF file
TKToru Kawakami
Toru Kawakami
NSNodoka Sekiguchi
Nodoka Sekiguchi
JKJun Kobayashi
Jun Kobayashi
TITatsuya Imi
Tatsuya Imi
KMKazuyuki Matsuda
Kazuyuki Matsuda
FIFumihiro Ishida
Fumihiro Ishida
Dysregulation of T-cell–mediated immunity is responsible for acquired pure red cell aplasia (PRCA). Although STAT3 mutations are frequently detected in patients with T-cell large granular lymphocytic leukemia (T-LGLL), which is often complicated by PRCA and which is also reported to be associated with acquired aplastic anemia (AA) and myelodysplastic syndrome (MDS), whether STAT3-mutated T cells are involved in the pathophysiology of PRCA and other types of bone marrow failure remains unknown. We performed STAT3 mutation analyses of the peripheral blood mononuclear cells from PRCA patients (n = 42), AA (n = 54), AA–paroxysmal nocturnal hemoglobinuria (AA-PNH; n = 7), and MDS (n = 21) using an allele-specific polymerase chain reaction and amplicon sequencing. STAT3 mutations were not detected in any of the 82 patients with AA/PNH/MDS but were detected in 43% of the 42 PRCA patients. In all 7 STAT3-mutation–positive patients who were studied, the STAT3 mutations were restricted to sorted CD8+ T cells. The prevalence of STAT3 mutation in idiopathic, thymoma-associated, autoimmune disorder–associated, and T-LGLL–associated PRCA was 33% (5 of 15), 29% (2 of 7), 20% (1 of 5), and 77% (10 of 13), respectively. The STAT3-mutation–positive patients were younger (median age, 63 vs 73 years; P= .026) and less responsive to cyclosporine (46% [6 of 13] vs 100% [8 of 8]; P= .0092) in comparison with STAT3-mutation–negative patients. The data suggest that STAT3-mutated CD8+ T cells may be closely involved in the selective inhibition of erythroid progenitors in PRCA patients. Key Points Somatic STAT3 mutations were frequently found in PRCA with or without T-LGLL. STAT3 mutation–positive PRCA patients were less responsive to cyclosporine treatment than mutation-negative patients. Visual Abstract

1 January 2016 in Clinica Chimica Acta
Verified
Journal Article
Closed access
ASAkane Sueki
Akane Sueki
KMKazuyuki Matsuda
Kazuyuki Matsuda
AYAkemi Yamaguchi
Akemi Yamaguchi
MUMasayuki Uehara
Masayuki Uehara
MSMitsutoshi Sugano
Mitsutoshi Sugano
THTakayuki Honda
Takayuki Honda

1 October 2018 in Cytokine
Verified
Journal Article
Closed access
TSTakahiro Shimodaira
Takahiro Shimodaira
KMKazuyuki Matsuda
Kazuyuki Matsuda
TUTakaaki Uchibori
Takaaki Uchibori
MSMitsutoshi Sugano
Mitsutoshi Sugano
TUTakeshi Uehara
Takeshi Uehara
THTakayuki Honda
Takayuki Honda

1 February 2017 in Cytokine
Verified
Journal Article
Closed access
TUTakaaki Uchibori
Takaaki Uchibori
KMKazuyuki Matsuda
Kazuyuki Matsuda
TSTakahiro Shimodaira
Takahiro Shimodaira
MSMitsutoshi Sugano
Mitsutoshi Sugano
TUTakeshi Uehara
Takeshi Uehara
THTakayuki Honda
Takayuki Honda

1 January 2021 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
AHAiko Hasegawa
Aiko Hasegawa
SSShoji Saito
Shoji Saito
SNShogo Narimatsu
Shogo Narimatsu
SNShigeru Nakano
Shigeru Nakano
MNMika Nagai
Mika Nagai
YNYozo Nakazawa
Yozo Nakazawa
Objectives: As the prognosis of relapsed/refractory (R/R) acute myeloid leukaemia (AML) remains poor, novel treatment strategies are urgently needed. Clinical trials have shown that chimeric antigen receptor (CAR)‐T cells for AML are more challenging than those targeting CD19 in B‐cell malignancies. We recently developed piggyBac‐modified ligand‐based CAR‐T cells that target CD116/CD131 complexes, also known as the GM‐CSF receptor (GMR), for the treatment of juvenile myelomonocytic leukaemia. This study therefore aimed to develop a novel therapeutic method for R/R AML using GMR CAR‐T cells.Methods: To further improve the efficacy of the original GMR CAR‐T cells, we have developed novel GMR CAR vectors incorporating a mutated GM‐CSF for the antigen‐binding domain and G4S spacer. All GMR CAR‐T cells were generated using a piggyBac‐based gene transfer system. The anti‐tumor effect of GMR CAR‐T cells was tested in mouse AML xenograft models.Results: Nearly 80% of the AML cells predominant in myelomonocytic leukaemia were found to express CD116. GMR CAR‐T cells exhibited potent cytotoxic activities against CD116+ AML cells in vitro. Furthermore, GMR CAR‐T cells incorporating a G4S spacer significantly improved long‐term in vitro and in vivo anti‐tumor effects. By employing a mutated GM‐CSF at residue 21 (E21K), the anti‐tumor effects of GMR CAR‐T cells were also improved especially in long‐term in vitro settings. Although GMR CAR‐T cells exerted cytotoxic effects on normal monocytes, their lethality on normal neutrophils, T cells, B cells and NK cells was minimal.Conclusions: GMR CAR‐T cell therapy represents a promising strategy for CD116+ R/R AML.